F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

Becton, Dickinson & Co. engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. It operates through the following segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment produces medical technologies and devices that are used to help improve healthcare delivery. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, and instruments and reagent systems to detect infectious diseases, healthcare-associated infections, and cancers. The BD Interventional segment offers vascular, urology, oncology, and surgical specialty products to hospitals, individual healthcare professionals, extended care facilities, alternate site facilities, and patients via its Homecare business. The company was founded by Maxwell W. Becton and Fairleigh S. Dickinson in 1897 and is headquartered in Franklin Lakes, NJ.

Beckman Coulter, Inc. manufactures and distributes biomedical testing instrument systems and general biomedical research products. It develops and markets products that simplify, automate and innovate complex biomedical testing. The firm’s systems operate in both diagnostics and life sciences laboratories on seven continents. Its products improve the productivity of medical professionals and scientists, supplying critical information for improving patient health and delivering trusted solutions for research and discovery. The company was founded in 1935 by Arnold O. Beckman and is headquartered in Brea, CA.

Laboratory Corp. of America Holdings operates as a life sciences company, which engages in the provision of vital information to help health professionals make clear and confident decisions. It operates through the Drug Development and Diagnostics segments. The Drug Development segment consists of lead optimization, preclinical safety assessment, analytical services, clinical trials, central laboratories, biomarkers, and companion diagnostics, market access, and technology solutions. The Diagnostics segment includes primary care, women's health, specialty medicine, oncology, ACOs, and hospitals and health systems. The company was founded in 1971 and is headquartered in Burlington, NC.

Siemens Healthcare Diagnostics, Inc. engages in the vitro diagnostics. It provides healthcare professionals in hospital, reference, and physician office laboratories and point-of-care settings with the vital information required to accurately diagnose, treat, and monitor patients. The company is headquartered in Tarrytown, NY.

Roche Diagnostics Operations, Inc. provides healthcare services. It offers commercial physical and biological research and development. The company is headquartered in Indianapolis, IN.

Novel Microdevices LLC is an American private company located in Baltimore, MD, that manufactures ultra-portable point-of-care molecular diagnostics systems. It was founded by Rohan Pais. Andrea Pais is currently the CEO of the firm.\nThe company says this about itself: About Novel Microdevices Novel Microdevices is a woman-owned, woman-led point-of-care infectious disease diagnostics company headquartered in Baltimore City, Maryland. Novel Microdevices is commercializing Novel Dx, a proprietary and best-in-class Point-of-Care (POC) rapid molecular diagnostics system that is ultra-portable and can be produced for a wide range of high-volume molecular diagnostic assay applications. The company is focusing on women’s health and under-resourced populations in the $31 billion infectious diseases diagnostics market with tests in development for multiple respiratory and sexually transmitted infections.

Theranos was a privately-held consumer healthcare technology company that is now arguably the largest biomedical fraud in U.S. history. Its founder, Elizabeth Holmes, was convicted of investor fraud after a series of Wall Street Journal (WSJ) articles that revealed the tests the company claimed to be doing were actually being carried out by traditional machines purchased from other companies. At its peak, it was valued at $10 billion.

Roche Diagnostics GmbH, part of Roche Holding AG, is a company headquartered in Mannheim, Germany, involved in laboratory analytical instruments. Andreas Schmitz and Claus Haberda are the current co-CEOs of the firm. On January 01, 1999 Roche Holding AG acquired Roche Diagnostics GmbH.

Fresenius Medical Care North America is a hospital and health care company that focuses on providing healthcare services to people with renal and other chronic conditions. It offers dialysis facilities, outpatient cardiac and vascular labs, and urgent care centers. Fresenius Medical Care North America (FMCNA) is one of the largest providers of dialysis products and services. It has raised a record amount of money to support the goals and initiatives of the National Kidney Foundation (NKF) over the course of a two-year partnership. Fresenius Medical Care North America was founded in 1996 by Bill Valle and it is headquartered in Waltham, Massachusetts.

Grifols Diagnostic Solutions, Inc. manufactures and markets plasma medicines and medical tools. Its services include blood group genotyping testing, IRL serology testing, prenatal testing, biological drug monitoring tests, FH genetic testing and other genetic testing. The company is headquartered in Emeryville, CA.

Femasys is a biomedical company focused on transforming women’s healthcare worldwide by developing novel solutions and next-generation advancements providing significant clinical impact to address severely underserved areas. With an initial focus in the area of reproductive health, its two lead product candidates offer solutions to improve patient care and health economics: FemBloc, a first and only non-surgical product for permanent birth control and FemaSeed, a first and only directed sperm delivery product for infertility treatment. Femasys’ FemVue product for fallopian tube assessment by ultrasound is currently marketed in the United States as its main commercial priority. Femasys has also developed a novel technology platform for tissue sampling intended to be marketed alongside our other women-specific medical products in the physician’s office setting.

SeLux Diagnostics, Inc. develops universal synthetic amplifier technology equipment. The firm offers Next Generation Phenotyping (NGP) platform that promises to transform infectious disease patient treatment by dramatically increasing the speed and accuracy with which targeted, personalized antibiotic therapies can be prescribed. The company was founded by Eric Stern and Aleksander Vacic in 2014 and is headquartered in Charlestown, MA.

Changsha Yonglekang Instrument Equipment Co., Ltd., established on 2006-04-12, The business scope includes special instruments and meters for environmental monitoring,Industrial automatic control system device,Experimental analysis instrument,Laboratory equipment and ventilation system,glassware,Manufacture of special equipment for environmental protection;electronics,General Machinery,Scientific Testing Instrument,Energy saving and environmental protection products,Class II medical device,Class III medical device sales;Environmental Technology Consulting,communication service,development services;software development;Software technology transfer;Software technical service;Electronic product development;Class I medical device production;Retailing of Class I Medical Devices;Environmental Engineering Design;Engineering Project Management Services;Environmental supervision of construction projects;Self-operated and agent import and export of various commodities and technologies,Except for the goods and technologies that the state restricts the company to operate or prohibits the import and export of;Safety Training.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

CUTISS AG can now bio-engineer large quantities of individually customized human skin grafts, denovoSkin™, starting off from a very small piece of healthy patient’s skin. Because of its intrinsic characteristics, denovoSkin™ is expected to result in a minimally scarring outcome after transplantation. denovoSkin™ received a Swissmedic, EMA and FDA Orphan drug designation for the treatment of burns.

Truvian disrupts the blood-testing industry by developing an automated, benchtop diagnostic system to provide lab-accurate results. The blood-testing system combines chemistry, immunoassays, and hematology assays in one device. With its 20-minute, single-run wellness panel that requires only several drops of blood, the company aims to cover about 40 commonly ordered diagnostic tests, including a lipid panel, metabolic panel, and complete blood cell count. Its dry reagent and optical sensing technologies, which require no refrigeration, can perform a complete blood count, basic metabolic and lipid panel, hemoglobin and glucose tests, thyroid screenings, and liver and kidney function exams. The company also offers Easy Check, a blood-based serologic test Truvian claims can detect the presence of the antibodies effective against SARS-CoV-2, the virus that causes COVID-19. Dena Marrinucci, Kim Kamdar, Mark Bowles, and Pieter van Rooyen established the San Diego, California-based company in 2015.